Saturday, April 27, 2024
Under this MoU, both sides have agreed to foster cooperation in the field of therapeutic innovations for autoimmune diseases, provide training
Agreement was signed at MoHAP premises by HE Dr. Youssif Al Serkal, Assistant Undersecretary for the Ministry’s Hospitals Sector, and Muhammad Abu Bakr Abdul-Jawad, General Manager, Gulf Cluster, AbbVie Biopharmaceuticals in the presence of HE. Dr. Mohammad Salim Al Olama, Undersecretary of the Ministry of Health and Prevention.
Expanding Global Partnerships
HE Dr. Youssif Al Serkal said: “The MoU reflects MoHAP’s keenness to expand its strategic partnership network with global companies, as part of its endeavors to provide autoimmune disease patients with new medicines, elevate the capabilities of health professionals, enhance healthcare awareness, and provide the best therapeutic services. This comes part of MoHAP’s strategy to provide an integrated healthcare service in accordance with the highest standards of excellence and professionalism and achieve leadership in the health field in line with the National Agenda 2021.”
Boosting Healthcare for Patients with Autoimmune Diseases
“This agreement would help provide training programs for MoHAP’s doctors, pharmacists, and nursing staff in the treatment of autoimmune diseases by dispatching them to MoHAP non-affiliated hospitals to receive clinical training. The MoU is focusing also on organizing educational workshops and lectures on autoimmune diseases and ways to prevent them,” Al Serkal concluded.
On his side, Muhammad Abu Bakr Abdul-Jawad said: “AbbVie is very keen to develop its partnership with MoHAP to provide effective treatment for patients with autoimmune diseases, as part of the company’s strenuous efforts to improve patients’ lives. The agreement states that AbbVie will provide its pharmaceutical innovations in the field of treatment of rheumatoid arthritis and psoriasis.”rship with MoHAP to provide effective treatment for patients with autoimmune diseases, as part of the company’s strenuous efforts to improve patients’ lives. The agreement states that AbbVie will provide its pharmaceutical innovations in the field of treatment of rheumatoid arthritis and psoriasis.”
.jpg)
